All posts by psufka

Favorite Abstracts from the 2017 ACR Annual Meeting

Our next #RheumJC session will be Thursday, November 30th at 10pm Eastern Time (click here to find this in your time zone).

We’ll be discussing four of our favorite abstracts from the recent #ACR17 Meeting in San Diego:

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis

Our next #RheumJC session will be Thursday, October 26th.

We’ll be discussing the article Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis epublished in Arthritis Care & Research

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Role of Blocking IL-1 with Canakinumab for Atherosclerotic Disease

Update 09/29/2017: Here is a Storify summary of our session: https://storify.com/psufka/rheumjc-from-09-28-2017 

Our next #RheumJC session will be Thursday, September 28th.

We’ll be discussing the recently published NEJM article Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Also refer to the associated editorial in NEJM, Targeting Inflammation in Coronary Artery Disease.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Guidelines on Perioperative Management of Antirheumatic Medication for Hip & Knee Arthroplasty

After a brief summer break, #RheumJC is back!

Our next session will be Thursday, July 27th, discussing the recently published guidelines in Arthritis Care & Research: 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Effect of methotrexate discontinuation on efficacy of influenza vaccination in RA

This week’s #RheumJC will be Thursday, May 25th, discussing the May 2017 Annals of the Rheumatic Diseases article: Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial by Dr. Jin Kyun Park, et al.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Spinal Manipulation in the Treatment of Low Back Pain

Our next #RheumJC discussion will be Thursday, April 27th, discussing the April 2017 JAMA article: Association of Spinal Manipulative Therapy With Clinical Benefit and Harm for Acute Low Back Pain: Systematic Review and Meta-analysis by Dr. Neil M. Paige, et al.

The publisher has graciously made this article free to access on April 26–27.

We also suggest the accompanying editorial: The Role of Spinal Manipulation in the Treatment of Low Back Pain.

Please note, our second session will be held one hour earlier than our usual time.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Changes in Ultrasonographic Vascularity with Adalimumab + MTX in RA

Our next #RheumJC discussion will be Thursday, March 30th, discussing the recent November 2016 Arthritis & Rheumatology article: Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate) by Dr. Gurjit S. Kaeley, et al. This article is open-access.

As an additional reference, we suggest the Nature Reviews Rheumatology article: Using ultrasonography to facilitate best practice in diagnosis and management of RA.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Use of Lesinurad with Allopurinol for Gout

Our next #RheumJC discussion will be Thursday, February 23rd, discussing the January 2017 Arthritis & Rheumatology article: Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study) by Dr. Kenneth G. Saag, et al. This article is open-access.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

#RheumJC joining #NephJC to look at the PRECISION Trial

Artwork by Holly Fischer [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons.

For our next journal club activity, we’ll be teaming up with the Nephrology Journal Club #NephJC to discuss the PRECISION Trial, published in NEJM: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis by Nissen SE, et al. This article is open access via the NephJC blog post.

As many of you may recall, a portion of this data was presented during the #ACR16 late breaking abstract session: 1L: The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis.

When:

Additional Details:

  • For this session, we’ll plan on using the #NephJC hashtag for the discussion, since they’ll be hosting the session.
  • As usual, we suggest using the website tchat.io in your desktop web browser as the best way to participate in the chat.

Favorite Abstracts from the 2016 ACR Annual Meeting

640px-tnf-alpha

The next session of #RheumJC will be Wednesday, December 14. We’ll be discussing four of your favorite abstracts from the 2016 ACR Annual Meeting based on your votes from our recent poll.

The abstracts we’ll be discussing are:

Abstract 911 – Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)

Abstract 1955 – Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)

Abstract 3028 – A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)

Abstract 1725 – Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.